Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 6/23/2025

Anaphylaxis Management

Introduction to Anaphylaxis

  • The American Academy of Allergy, Asthma, and Immunology recommends epinephrine as the first-line treatment for moderate to severe allergic reactions, and it should be administered immediately when anaphylaxis is suspected 1
  • Allergic reactions can be classified according to severity using the modified Ring and Messmer scale, which includes four grades of severity, from skin/mucosal signs only to cardiac or respiratory arrest 1

Classification of Allergic Reactions

Grade Clinical Signs
I Skin/mucosal signs only: generalized erythema, urticaria, angioedema
II Moderate multi-organ involvement: skin/mucosal signs with moderate hypotension, tachycardia, moderate bronchospasm or gastrointestinal symptoms
III Life-threatening mono- or multi-organ involvement: severe hypotension, tachycardia/bradycardia, severe bronchospasm, skin/mucosal signs, or gastrointestinal symptoms
IV Cardiac or respiratory arrest

1

First-Line Treatment

  • The American Academy of Allergy, Asthma, and Immunology recommends epinephrine IM as the first-line treatment, administered into the anterolateral thigh, and may be repeated every 5-15 minutes as needed 1
  • For adults and children, the dose of epinephrine is 0.3-0.5 mg (0.3-0.5 mL of 1:1000 solution) 1

Airway Management

  • The British Journal of Anaesthesia recommends administering 100% oxygen and positioning the patient appropriately 2
  • For bronchospasm, albuterol via MDI (4-8 puffs for children; 8 puffs for adults) or nebulized solution (1.5 mL for children; 3 mL for adults) is recommended 1

Circulation Support

  • The American Academy of Allergy, Asthma, and Immunology recommends placing the patient in a recumbent position with legs elevated if hypotensive, and administering IV fluids, such as a rapid infusion of 10-20 mL/kg for hypotension 1, 2
  • For refractory hypotension, additional epinephrine doses, vasopressors, or glucagon 1-5 mg IV (adults) or 20-30 μg/kg (children, max 1 mg) may be considered, especially for patients on beta-blockers 1, 3

Adjunctive Treatments

  • The American Academy of Allergy, Asthma, and Immunology recommends H1 antihistamine, such as diphenhydramine 1-2 mg/kg (maximum 50 mg) IV or oral, and H2 antihistamine, such as ranitidine 1-2 mg/kg (maximum 75-150 mg) IV or oral 1
  • Corticosteroids, such as prednisone 1 mg/kg (maximum 60-80 mg) oral or methylprednisolone 1 mg/kg (maximum 60-80 mg) IV, may also be used 1

Monitoring and Follow-Up

  • Patients should be monitored for 4-6 hours or longer based on reaction severity, and extended observation (8-24 hours) may be necessary for patients with severe initial reactions, history of biphasic reactions, or comorbid conditions 1
  • The American Academy of Allergy, Asthma, and Immunology recommends follow-up with a primary care provider and consideration of referral to an allergist/immunologist 1

Patient Education

  • Patients should be educated on allergen avoidance, recognition of anaphylaxis symptoms, proper use of epinephrine auto-injector, and when to seek emergency care, and should be provided with medical identification jewelry or an anaphylaxis wallet card 1

High-Risk Patients

  • Patients with asthma, mast cell disorders, cardiovascular disease, and those taking beta-blockers or ACE inhibitors are at higher risk for severe reactions 2
  • Biphasic reactions can occur up to 72 hours after the initial reaction, although this fact is from a less preferred source, it is still notable 4